Markers of Bone Turnover for Monitoring Treatment of Osteoporosis with Antiresorptive Drugs

Delmas, P.D.

doi:10.1007/s001980070007

Cited by 107 publications

(69 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been well demonstrated how antiresorptive agents reduce the rate of bone remodeling with a decrease in bone resorption and bone formation markers (9)(10)(11)(12). In the present study we observed the changes in bone markers in patients who were taking two classes of anabolic agents and who had previously been on bisphosphonates.…”

Section: Discussionsupporting

confidence: 49%

Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates

Sousa

Diniz

Marques

et al. 2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

OBJECTIVE: To evaluate the responses of serum β-CTX and osteocalcin in patients who were undergoing treatment with teriparatide or strontium ranelate (SR). SUBJECTS AND METHODS: We analyzed 14 patients (12 women and 2 men; mean age of 71 years) taking teriparatide, and 13 female patients (mean age of 70 years) taking SR; all the patients having previously been on bisphosphonates. Serum β-CTX and osteocalcin levels were determined before and after the first and third months of teriparatide treatment and up to the fourth month of treatment with SR. RESULTS: We observed an initial significant increase in osteocalcin levels during the first month (165%, p = 0.01) followed by a peak of β-CTX (180%, p = 0.02) after the third month of treatment with teriparatide. An increase in these markers was also observed with SR: 49% in osteocalcin (p = 0.002) and 80% in β-CTX (p = 0.008). CONCLUSION: SR had a predominantly short-term bone-forming effect in postmenopausal women with osteoporosis previously treated with bisphosphonates in a lesser degree than with teriparatide.

show abstract

Section: Discussionsupporting

confidence: 49%

Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates

Sousa

Diniz

Marques

et al. 2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Recent data from RLX trials have demonstrated that RLX reduces the relative risk of incident vertebral fractures to a level comparable to that observed with bisphosphonates [1, [17][18][19], although RLX induces smaller increase in BMD compared with bisphosphonates [16]. Therefore, RLX has been considered to exert its beneficial effects on bone not by increasing BMD as mentioned above, but rather mainly by improving 'bone quality', [17,18,22] indicating bone turnover markers as one of the best ways to estimate the therapeutic effects of RLX on bone at a clinical level [18,22,23]. In our study, both BAP and NTx significantly decreased, and the decrease of NTx was earlier and greater than that of BAP as reported in the previous studies [5].…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of 1-year Treatment with Raloxifene on Bone and Lipid Metabolism in Japanese Postmenopausal Women with Osteoporosis

et al. 2007

View full text Add to dashboard Cite

Abstract. It has been well established that raloxifene (RLX) has beneficial effects on bone primarily in Caucasian women. However, to date, there is a dearth of data for Japanese postmenopausal women. In this study, we prospectively evaluated the effects of RLX on bone and lipid metabolism in fifty Japanese postmenopausal patients with untreated osteoporosis. We measured bone mineral density (BMD) by dual-energy X-ray absorptiometry at 7 sites including the lumbar spine, femoral neck, and distal radius. BMD was significantly increased at the lumbar spine both at 6 months and at 12 months compared with at baseline (p<0.01 for both), although the possibility could not be completely excluded that this increase may be partly explained by an apparent increase induced by degenerative changes in lumbar vertebrae since we had no control subjects to compare and be more certain of the findings in this study. Both bone-specific alkaline phosphatase (BAP) and serum N-terminal telopeptide of type I collagen (NTx) significantly decreased both at 6 months (p<0.01 for both) and at 12 months (p<0.01 for both) compared with at baseline, but not below the lower limit of the reference value. Total cholesterol and low-density lipoprotein cholesterol were significantly improved while triglycerides and high-density lipoprotein cholesterol were unaltered. Although longer and larger studies with fracture endpoints are needed to draw definite conclusions, our findings suggest the favorable effects of RLX on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis as in Caucasian women.

show abstract

“…[5] Bu nedenle, tedavi öncesi ölçülen bir yıkım belirtecinin, 3. ay sonunda tekrar ölçümü, postmenopozal osteoporozda kullanılan ilaçların etkinliğinin değerlendirilmesinde kullanışlı bir yön-tem olarak öne sürülmüştür. [11,12] Takiplerde, ölçülen değerlerin menopoz öncesi dönemdeki düzeylere çık-masının, tedavi gerekliliğini ortadan kaldırmadığı kabul edilmektedir. [13] Sağlıklı bireylerde menopoz öncesi NTx düzeylerinin bilinmesi, ileri dönemlerde yapılacak değerlendirmeler için yol gösterici olabilir.…”

Section: Discussionunclassified

A comparison of the measurements with biochemical markers of bone turnover and bone mineral density in the assessment of the efficiency of osteoporosis treatment

Ataoğlu

Atik

Gül³

et al. 2013

Eklem Hastalik Cerrahisi

View full text Add to dashboard Cite

Amaç: Bu çalışmada osteoporoz tedavisinin etkinliğinin değerlendirilmesinde kemik döngüsü biyokimyasal belirteçleri ve kemik mineral yoğunluğu (KMY) ölçümleri karşılaştırıldı. Hastalar ve yöntemler: Mart 2006 -Aralık 2008 tarihleri arasında kliniğimizde osteoporozlu 166 hasta çalışmaya alındı. Takiplerde ölüm ya da başka nedenlerle kontrolleri tamamlanamayan hastalar çalışmadan çıkarıldı. Daha önce herhangi bir osteoporoz tedavisi almamış olan ve çalış-mayı tamamlayan osteoporozlu 60 hastanın (49 kadın, 11 erkek; ort. yaş 65.7 yıl; dağılım 42-87 yıl) KMY ölçümleri ile çapraz bağlı N-telopeptid (NTx) değerleri kullanılarak idrarda kemik döngüsü biyokimyasal belirteçleri ölçümleri karşılaştırıldı. Bulgular: Hastaların 29'una (%48.3) cerrahi tedavi, 31'ine (%51.7) konservatif tedavi uygulandı. Hastaların ölçülen idrar NTx değerlerinde 3. ayda %38.82; 6. ayda %51.99; 12. ayda %66.41 azalma saptandı. Lomber vertebra KMY bir yıl sonunda %20.7 artarken, femur boyun KMY'de %11.9 artış saptandı. Sonuç: İdrar NTx değeri, KMY ölçümlerine kıyasla, osteoporoz tedavisine daha hızlı yanıt verdiği için, bu parametrenin tedavi etkinliğinin izleminde kullanılması uygun olabilir.Anahtar sözcükler: Kemik mineral yoğunluğu; çapraz bağlı N-telopeptid; osteoporoz; idrar. Objectives:This study aims to compare the measurements using biochemical markers of bone turnover and bone mineral density (BMD) in the assessment of the efficiency of osteoporosis treatment. Patients and methods: Between March 2006 and December 2008, 166 patients with osteoporosis in our clinic were included. Patients who were out of contact due to death or other reasons during follow-up were excluded. We compared the measurements of urinary biochemical markers of bone turnover using cross-linked N-telopeptide (Ntx) values and BMD in 60 patients (49 females, 11 males; mean age: 65.7 years; range: 42 to 87 years) with osteoporosis who were treatment-naive and completed study. Results: Twenty-nine (48.3%) of the patients received surgical treatment, while 31 (51.7%) received conservative therapy. Urine NTx values of the patients decreased 38.82% at three months; 51.99% at six months and 66.41% at 12 months. Lumbar vertebra BMD increased by 20.7% and femur neck BMD increased by 11.9% at the end of the first year. Conclusion: Urine NTx values respond to osteoporosis treatment faster than BMD measurements; thereby it may be suitable to use this parameter for the monitorization of the treatment efficiency.

show abstract

Markers of Bone Turnover for Monitoring Treatment of Osteoporosis with Antiresorptive Drugs

Cited by 107 publications

References 40 publications

Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates

Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates

Clinical Significance of 1-year Treatment with Raloxifene on Bone and Lipid Metabolism in Japanese Postmenopausal Women with Osteoporosis

A comparison of the measurements with biochemical markers of bone turnover and bone mineral density in the assessment of the efficiency of osteoporosis treatment

Contact Info

Product

Resources

About